DR54.2 DataRelease
Release Date: February 2025
New Studies: 14
Updated Studies: 11
New Studies
| SDY2470: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination SLVP015 2016 | ||||||||||
| Status: | New | |||||||||
| Description: | Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3OTD0Z7JJ | |||||||||
| Subjects: | 103 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: | None | |||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| SDY2485: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination SLVP015 2015 | ||||||||||
| Status: | New | |||||||||
| Description: | Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3NGUZLCHS | |||||||||
| Subjects: | 103 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: | None | |||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| SDY2914: Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors | |||||||||||
| Status: | New | ||||||||||
| Description: | Tumors from six mice in each group were minced into small pieces in cold RPMI 1640 medium, transferred into the gentleMACS C Tube containing the enzyme mix from Tumor Dissociation Kit (Miltenyi Biotec, 130-096-730), and then digested in gentleMACS Octo Dissociator, followed by filtration with 70 mm cell strainers.Filtered cells were purified by percoll gradient centrifugation as previously described to obtain leukocyte, and enriched by CD45 MicroBeads Kit (Miltenyi Biotec, 130-052-301) and suspended in FACS buffer.Obtained single-cell suspension was sent to Houston Methodist Research Institute ImmunoMonitoring Core for blocking, staining, washing and CyTOF detection. After mass cytometry (CyTOF) acquisition, raw measurement data (FCS files) and all metadata were preprocessed for concatenation, normalization, and compensation using CATALYST in R software. Dead cells were manually removed using FlowJo. Cell clustering was conducted as previously described using custom R scripts based on the FlowSOM and ConsensusClusterPlus, CATALYST, and Rtsne. By default, marker expression data transformation was performed using the prepData() SCE constructor arcsinh transform function with a cofactor of 5. The cluster merging and annotation were conducted based on heatmaps of marker expression in cell populations. Color in the heatmap represents the median of the arcsinh, 0-1 transformed marker expression was calculated for cells from all samples, the lineage markers, and cells in each sample individually, for the signaling marker. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3M02ERG3V | ||||||||||
| Subjects: | 4 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: | None | ||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: | None | ||||||||||
| SDY2948: Gene expression profile and active TB risk association with HLA class II alleles | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Several HLA allelic variants have been associated with protection from or susceptibility to infectious and autoimmune diseases. Here, we examined whether specific HLA alleles would be associated with different Mycobacterium tuberculosis (Mtb) infection outcomes. The HLA alleles present at the -A, -B, -C, -DPA1, -DPB1, -DQA1, -DQB1, -DRB1, and -DRB3/4/5 loci were determined in individuals with known Mtb infection outcomes. We found that DQA1*03:01, DPB1*04:02, and DRB4*01:01 were significantly more frequent in individuals with active TB (susceptibility alleles), while DPB1*105:01 was associated with protection from active TB. Peripheral blood mononuclear cells (PMBCs) from a subset of individuals were stimulated with Mtb antigens, revealing individuals who express any of the three susceptibility alleles were associated with lower magnitude of responses. Furthermore, we defined a gene signature associated with individuals expressing the susceptibility alleles that was characterized by lower expression of APC-related genes. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3DAI1PIQP | ||||||||||||
| Subjects: | 636 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY2951: Pharmacokinetics and Biodistribution of 16,16 dimethyl Prostaglandin E2 in Non-Irradiated and Irradiated Mice and Non-Irradiated Non-Human Primates | |||||||||||||||||||||||||
| Status: | New | ||||||||||||||||||||||||
| Description: | Exposure to high dose ionizing radiation can lead to life-threatening injuries and mortality. Bone marrow is the most sensitive organ to radiation damage, resulting in the hematopoietic acute radiation syndrome (H-ARS) with the potential sequelae of infection, hemorrhage, anemia, and death if untreated. The development of medical countermeasures (MCMs) to protect or mitigate radiation injury is a medical necessity. In our well-established murine model of H-ARS we have demonstrated that the prostaglandin E2 (PGE2) analog 16,16 dimethyl-PGE2 (dmPGE2) has survival efficacy as both a radioprotectant and radiomitigator. The purpose of this study was to evaluate the pharmacokinetics (PK) and biodistribution of dmPGE2 in irradiated and non-irradiated inbred C57BL/6J mice, PK in irradiated and non-irradiated Jackson Diversity Outbred (JDO) mice, and the PK profile of dmPGE2 in non-irradiated non-human primates (NHPs). The C57BL/6J and JDO mice each received a single subcutaneous (SC) dose of 35 ug of dmPGE2 and were randomized to either receive radiation 30 min later or remain non-irradiated. Plasma and tissue PK profiles were established. The NHP were dosed with 0.1mg/kg by SC administration and the PK profile in plasma was established. The concentration time profiles were analyzed by standard non-compartmental analysis and the metrics of AUC0-Inf, AUC60-480 (AUC from 60-480 minutes), Cmax, and t1/2 were evaluated. AUC60-480 represents the post irradiation time frame and was used to assess irradiation effect. | ||||||||||||||||||||||||
| Program/Contract: |
|
||||||||||||||||||||||||
| DOI: | 10.21430/M33TEX2T16 | ||||||||||||||||||||||||
| Subjects: | 0 | ||||||||||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||||||||||
| Publications: |
|
||||||||||||||||||||||||
| Resources: |
|
||||||||||||||||||||||||
| Assays: | None | ||||||||||||||||||||||||
| Clinical Assessments: | None | ||||||||||||||||||||||||
| SDY2958: Type 2 inflammation reduces SARS-CoV-2 replication in the airway epithelium in allergic asthma through functional alteration of ciliated epithelial cells I | |||||||
| Status: | New | ||||||
| Description: | Bronchial AECs from healthy nonsensitized children (n= 17) and children with allergic asthma (n= 15) aged 6 to 18 years (Tables I and II) were obtained from subjects while under general anesthesia; the cells were obtained by using 4-mm Harrell unsheathed bronchoscope cytology brushes (ConMed, Utica, NY). As we and others have described33,34 an unprotected brush was inserted through an endotracheal tube, advanced until resistance was felt, and rubbed against the airway surface for 2 seconds. Cells were then seeded onto T-25 cell culture flasks precoated with type I collagen and proliferated under submerged culture conditions | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3W2K172DX | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY2959: Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus | ||||||||||||||||
| Status: | New | |||||||||||||||
| Description: | Understanding the immune responses to SARS-CoV-2 vaccination is critical to optimizing vaccination strategies for individuals with autoimmune diseases, such as systemic lupus erythematosus (SLE). Here, we comprehensively analyzed innate and adaptive immune responses in 19 patients with SLE receiving a complete 2-dose Pfizer-BioNTech mRNA vaccine (BNT162b2) regimen compared with a control cohort of 56 healthy control (HC) volunteers. Patients with SLE exhibited impaired neutralizing antibody production and antigen-specific CD4+ and CD8+ T cell responses relative to HC. Interestingly, antibody responses were only altered in patients with SLE treated with immunosuppressive therapies, whereas impairment of antigen-specific CD4+ and CD8+ T cell numbers was independent of medication. Patients with SLE also displayed reduced levels of circulating CXC motif chemokine ligands, CXCL9, CXCL10, CXCL11, and IFN-γ after secondary vaccination as well as downregulation of gene expression pathways indicative of compromised innate immune responses. Single-cell RNA-Seq analysis reveals that patients with SLE showed reduced levels of a vaccine-inducible monocyte population characterized by overexpression of IFN-response transcription factors. Thus, although 2 doses of BNT162b2 induced relatively robust immune responses in patients with SLE, our data demonstrate impairment of both innate and adaptive immune responses relative to HC, highlighting a need for population-specific vaccination studies. | |||||||||||||||
| Program/Contract: |
|
|||||||||||||||
| DOI: | 10.21430/M3V1RASA10 | |||||||||||||||
| Subjects: | 0 | |||||||||||||||
| Study PI, contact: |
|
|||||||||||||||
| Publications: |
|
|||||||||||||||
| Resources: |
|
|||||||||||||||
| Assays: |
|
|||||||||||||||
| Clinical Assessments: | None | |||||||||||||||
| SDY2962: SARS-CoV-2 and Influenza A Virus Coinfections in Ferrets | ||||||||||
| Status: | New | |||||||||
| Description: | Ferrets were coinfected with SARS-CoV-2 and human seasonal influenza A viruses (IAVs; H1N1 or H3N2) and were compared to animals that received each virus alone | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3X2ANDCDF | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| SDY2963: A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes | |||||||
| Status: | New | ||||||
| Description: | Seasonal influenza vaccines offer little protection against pandemic influenza virus strains. It is difficult to create effective prepandemic vaccines because it is uncertain which influenza virus subtype will cause the next pandemic. In this work, we developed a nucleoside-modified messenger RNA (mRNA)-lipid nanoparticle vaccine encoding hemagglutinin antigens from all 20 known influenza A virus subtypes and influenza B virus lineages. This multivalent vaccine elicited high levels of cross-reactive and subtype-specific antibodies in mice and ferrets that reacted to all 20 encoded antigens. Vaccination protected mice and ferrets challenged with matched and mismatched viral strains, and this protection was at least partially dependent on antibodies. Our studies indicate that mRNA vaccines can provide protection against antigenically variable viruses by simultaneously inducing antibodies against multiple antigens. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3ZUEULG98 | ||||||
| Subjects: | 158 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: |
|
||||||
| SDY2964: Insights into the Chemical Exposome during Pregnancy: A Non-Targeted Analysis of Preterm and Term Births | ||||||||||
| Status: | New | |||||||||
| Description: | Human-made chemicals are ubiquitous, leading to chronic exposure to complex mixtures of potentially harmful substances. We investigated chemical exposures in pregnant women in New York City by applying a non-targeted analysis (NTA) workflow to 95 paired prenatal urine and serum samples (35 pairs of preterm birth) collected as part of the New York University Children's Health and Environment Study. We analyzed all samples using liquid chromatography coupled with Orbitrap high-resolution mass spectrometry in both positive and negative electrospray ionization modes, employing full scan and data-dependent MS/MS fragmentation scans. We detected a total of 1524 chemical features for annotation, with 12 chemicals confirmed by authentic standards. Two confirmed chemicals dodecyltrimethylammonium and N,N-dimethyldecylamine N-oxide appear to not have been previously reported in human blood samples. We observed a statistically significant differential enrichment between urine and serum samples, as well as between preterm and term birth (p < 0.0001) in serum samples. When comparing between preterm and term births, an exogenous contaminant, 1,4-cyclohexanedicarboxylic acid (tentative), showed a statistical significance difference (p = 0.003) with more abundance in preterm birth in serum. An example of chemical associations (12 associations in total) observed was between surfactants (tertiary amines) and endogenous metabolites (fatty acid amides). | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3Z9U7J8RM | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| SDY2965: Influenza Vaccination | |||||||
| Status: | New | ||||||
| Description: | In this study, we compared vaccine-induced humoral immune responses induced by seasonal influenza vaccination with inactived vaccine (IIV/Fluzone) and live attenuated mucosal vaccine (LAIV/FluMist) in humans. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3WBGCDKFD | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY2966: Ab Responses to HA mRNA | ||||||||||
| Status: | New | |||||||||
| Description: | Mice were vaccinated with mRNA-HA and assessed for immune responses | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3UPGIPX6O | |||||||||
| Subjects: | 120 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: |
|
|||||||||
| SDY2967: Zinc Carnosine Metal-Organic Coordination Polymer as a Potent Influenza Vaccine Platform | |||||||
| Status: | New | ||||||
| Description: | Evaluation of Zinc Carnosine Metal-Organic coordination polymer as a delivery vehicle for COBRA HA Y2 and the adjuvant CpG. Immunogenicity was assessed in vivo in mice vaccinated with Y2 and CpG complexed with ZnCar, demonstrating improved humoral and cellular responses compared to mice vaccinate with Y2 and CpG only. The ZnCar complex shows superiority in storage stability as well. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3THVHFSFN | ||||||
| Subjects: | 90 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: |
|
||||||
| SDY2968: COVID-19 vaccination perspectives among patients with Long COVID: A qualitative study | ||||||||||
| Status: | New | |||||||||
| Description: | Individuals who have Long COVID may have unique perspectives about COVID-19 vaccination due to the significant impact that COVID-19 has had on their lives. However, little is known about the specific vaccination perspectives among this patient population. The goal of our study was to improve our understanding of perspectives about COVID-19 vaccines among individuals with Long COVID. Interviews were conducted with patients receiving care at a post-COVID recovery clinic. Deductive thematic analysis was used to characterize participant perspectives according to the vaccine acceptance continuum framework, which recognizes a spectrum from vaccine acceptance to refusal. From interviews with 21 patients, we identified perspectives across the continuum of vaccine acceptance. These perspectives included acceptance of vaccines to prevent future illness, concerns about vaccine side effects on Long COVID symptoms, and refusal of vaccines due to perceived natural immunity. A limitation of our study is that these perspectives are specific to individuals receiving care at one post-COVID recovery clinic. In conclusion, our study demonstrates that some patients with Long COVID are uncertain about COVID-19 vaccines and boosters but may also be amenable to conversations that impact future vaccination acceptance. Patient perspectives should be considered when communicating recommendations for COVID-19 vaccinations to this population. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3J8UMVGT6 | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
Updated Studies
| SDY406: Immune Responses to Influenza-Like Illness SLVP022 2013 through 2018 | |||||||||||||||
| Status: | Updated | ||||||||||||||
| Description: | To investigate the nasal transcriptional response and peripheral plasmablast response in acute influenza infection | ||||||||||||||
| Program/Contract: |
|
||||||||||||||
| DOI: | 10.21430/M3U4SDFNWN | ||||||||||||||
| Subjects: | 86 | ||||||||||||||
| Study PI, contact: |
|
||||||||||||||
| Publications: | None | ||||||||||||||
| Resources: |
|
||||||||||||||
| Assays: |
|
||||||||||||||
| Clinical Assessments: | None | ||||||||||||||
| SDY1467: B-cell Immunity to Influenza SLVP017 2009 | |||||||||
| Status: | Updated | ||||||||
| Description: | Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3BNBGK39S | ||||||||
| Subjects: | 51 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY1481: Genetic and Environmental Factors in the Response to Influenza Vaccination 2014 | |||||||||||
| Status: | Updated | ||||||||||
| Description: | This is a phase IV study of 120 healthy 12-49 year old adolescents and adult volunteers who are given licensed seasonal influenza vaccine. There are no exclusions for gender, ethnicity or race. The volunteers will be enrolled into one of 3 groups: Group A: Up to 40 healthy monozygotic (MZ) twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4). Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+ 7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs). Group B: Up to 40 healthy dizygotic (DZ) twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4). Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs). Group C: Up to 40 healthy monozygotic (MZ) twin volunteers, 12-49 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) or live, attenuated influenza vaccine quadrivalent (LAIV4). Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs). This group was discontinued in 2016 due to ACIP recommendations against the use of LAIV but may be reopened in 2018 pending LAIV4 availability. Each twin is counted as a single participant. All reporting numbers reflect the number of participants, not the number of twin pairs. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3KVQXST4E | ||||||||||
| Subjects: | 114 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: |
|
||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: | None | ||||||||||
| SDY1483: Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029) | |||||||||
| Status: | Updated | ||||||||
| Description: | This is a study of healthy children and adults receive the current seasonal influenza vaccine. The volunteers were enrolled into one of 7 groups over a 5-year period. Immunization is administered; blood samples and NP swabs are collected at various time points based on groups assigned. Group A (LAIV4/annual return), Group B (LAIV4/ single year), Group C (LAIV4/NP swab group), Group D (IIV4/annual return), Group E (IIV4/single year), Group F (LAIV4/single year), Group G (IIV4/single year) | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M34YFGITWS | ||||||||
| Subjects: | 79 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY1484: Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection (SLVP030) | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | This is a Phase IV study of up to 100 healthy children, ages 6 months to 10 years of age, who will receive either Flumist live, attenuated influenza virus vaccine, quadrivalent (LAIV4) or the current Fluzone inactivated influenza vaccine, quadrivalent (IIV4). The volunteers will be enrolled into one of 3 Groups (A, B, C). Volunteers will return each year until 2018-2019 for annual flu immunizations and study visits. Questionnaires will be administered annually to record demographic characteristics, vaccination history, exposure to animals, day care and medically attended illness. There are no exclusions for gender, ethnicity or race. Volunteers in Group C will also receive the measles, mumps, rubella and varicella (MMRV) vaccine at approximately 12-15 months of age (to be administered by the volunteers' personal pediatrician, not as a study vaccine). They will then come for a study visit to collect blood 60 days later. Each twin is counted as a single participant. All reporting numbers reflect the number of participants, not the number of twin pairs. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3VRIZVVE5 | ||||||||||||
| Subjects: | 81 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY2497: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | Investigators will carry out an in-depth study of human B cell and T cell immune responses to vaccines that the person hasn't previously encountered, as well as to seasonal influenza vaccination, and determine which aspects of immune function are most affected by aging in each case. The research subjects are a well-characterized longitudinal cohort of young and elderly individuals whose influenza vaccine responses have been studied each year for up to 9 years, and who will be vaccinated for Hepatitis A in this new study. Improved understanding of human immune system function obtained by studying individual B cells and T cells and their fates following vaccination will help in the design and testing of new vaccines against emergent diseases. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3Y7FDJGD6 | ||||||||||||
| Subjects: | 57 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: | None | ||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY2531: Engineered Influenza Virus Virions Reveal the Contributions of Non-hemagglutinin Structural Proteins to Vaccine-Mediated Protection | |||||||||
| Status: | Updated | ||||||||
| Description: | The development of improved and universal anti-influenza vaccines would represent a major advance in the protection of human health. In order to facilitate the development of such vaccines, understanding how viral proteins can contribute to protection from disease is critical. Much of the previous work to address these questions relied on reductionist systems (i.e., vaccination with individual proteins or virus- like particles [VLPs] that contain only a few viral proteins); thus, we have an incomplete understanding of how immunity to different subsets of viral proteins contributes to protection. Here, we report the development of a platform in which a single viral protein can be deleted from an authentic viral particle that retains the remaining full complement of structural proteins and viral RNA. As a first study with this system, we chose to delete the major influenza A virus (IAV) antigen, the hemagglutinin (HA) protein, to evaluate how the other components of the viral particle contribute en masse to protection from influenza disease. Our results show that while anti-HA immunity plays a major role in protection from challenge with a vaccine-matched strain, the contributions from other structural proteins were the major drivers of protection against highly antigenically drifted, homosubtypic strains. This work highlights the importance of evaluating the inclusion of non-HA viral proteins in the development of broadly efficacious and long-lasting influenza vaccines. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3TX82XYNN | ||||||||
| Subjects: | 90 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: |
|
||||||||
| SDY2661: Broadly Reactive H2 Hemagglutinin Vaccines Elicit Cross-Reactive Antibodies in Ferrets Preimmune to Seasonal Influenza A Viruses | |||||||||
| Status: | Updated | ||||||||
| Description: | In this study, previously described H2 computationally optimized broadly reactive antigen (COBRA) hemagglutinin vaccines (Z1 and Z5) were tested in influenza virus | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3CWE7D59L | ||||||||
| Subjects: | 180 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: |
|
||||||||
| SDY2917: Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | A prospective cohort study was conducted at 2 academic medical centers between September 20, 2023 and March 21, 2024, enrolling 124 individuals who received the respiratory syncytial virus vaccine during pregnancy. Infant capillary blood was collected at 2 months of age from 29 of the infants. Maternal and cord immunoglobulin G levels achieved by respiratory syncytial virus vaccination were compared to those associated with maternal natural respiratory syncytial virus infection, using banked blood from 20 maternal:cord dyads collected prior to the availability of the maternal respiratory syncytial virus vaccine. Levels of immunoglobulin G against respiratory syncytial virus strain A2 and B fusion (F) and attachment (G) proteins and against pertussis toxin (as a comparator antigen from a vaccine routinely administered earlier in pregnancy) were measured using a Binding Antibody Multiplex Assay. Differences in titers between vaccination and natural infection were examined using Wilcoxon rank-sum test. Differences in cord:maternal transfer ratios and 2-month infant antibody levels by timing of maternal vaccination were evaluated by Kruskal-Wallis testing. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3E6U41NW0 | ||||||||||||
| Subjects: | 171 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: | None | ||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY2931: SeroNet Longitudinal Study v4.2.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Status: | Updated | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Description: | The longitudinal serosurveillance study aimed to understand the immune responses to COVID-19 vaccination and SARS-CoV-2 infection. Between 2021 and 2024, four Capacity Building Centers (CBC) collected samples from 3284 participants (3119 are being released), including healthy and immunocompromised populations. Demographic and clinical data were collected for all participants, with 61% female, ages ranged from 0 to > 89 years, and 68% white. Among the 1,806 participants in the general population, 901 were in the Healthy cohort (no reported comorbidities), and 905 were in the Comorbidity cohort (with 1 or more reported comorbidities or chronic conditions). CBCs collected more detailed information from participants in select cohorts (e.g. time of diagnosis, treatment): 824 in Cancer, 162 in IBD, 146 in HIV and 181 transplant recipients. There were on average 4.7 visits per participant. Collection timepoints were strategically aligned for before and after vaccine administration or infection: 30, 60, 90, 120, 180 and 360 days. Vaccination status for participants range from unvaccinated to vaccinated with homologous and heterologous primary series and booster doses. Vaccines used were the licensed mRNA-based vaccines in the large majority of Janssen protein subunit vaccine in X% of cases. Data harmonization was achieved through SeroNet templates submitted by each CBC, validated for business rule compliance, then shipped to the NCI FNL Central Repository | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Program/Contract: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DOI: | 10.21430/M3AXZXJN91 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Subjects: | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Publications: | None | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Resources: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assays: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clinical Assessments: | None | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SDY2934: CpG ACE-Dextran MP | |||||||||
| Status: | Updated | ||||||||
| Description: | CpG MP expressing COBRA elicits broadly reactive antibodies | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3BYLWXJNY | ||||||||
| Subjects: | 52 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: |
|
||||||||